Department of Pharmacy, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Ren Fail. 2013;35(3):418-20. doi: 10.3109/0886022X.2012.761085. Epub 2013 Jan 29.
Linezolid (LZD) is an option for treating infections caused by multi-resistant Gram-positive bacteria. The protein-binding rate of LZD markedly influences its elimination by dialysis, with limited data suggesting that LZD is cleared by intermittent hemodialysis. Here, we investigated the protein-binding rate and elimination efficiency of LZD in a sepsis patient receiving dialysis. The oral administration of LZD at 600 mg/day resulted in protein-binding and free rates of the drug of 20.4% and 79.6%, respectively, 24 h after administration. By comparing the LZD concentration before and after dialysis, the elimination efficiency of free LZD as a result of dialysis was found to be 40.6%. Our sepsis patient showed higher plasma concentrations of LZD at trough after hemodialysis than the reported concentrations in normal renal function patients. However, it is not clear from our present findings if a relationship exists between myelosuppression and plasma LZD concentration.
利奈唑胺（LZD）是治疗多重耐药革兰阳性菌感染的选择之一。LZD 的蛋白结合率显著影响其通过透析的清除率，有限的数据表明 LZD 通过间歇性血液透析清除。在这里，我们研究了接受透析的脓毒症患者中 LZD 的蛋白结合率和消除效率。LZD 口服 600mg/天，给药后 24 小时，药物的蛋白结合率和游离率分别为 20.4%和 79.6%。通过比较透析前后 LZD 的浓度，发现透析导致游离 LZD 的消除效率为 40.6%。我们的脓毒症患者在血液透析后 LZD 的谷浓度高于正常肾功能患者的报告浓度。然而，从我们目前的研究结果来看，骨髓抑制与血浆 LZD 浓度之间是否存在关系尚不清楚。
